Silicon Agent That Makes Hydrogen Protects Intestines From Damage
- Authors
- Masato Shimada, Yoshihisa Koyama, Yuki Kobayashi, Yasunari Matsumoto, Hikaru Kobayashi, Shoichi Shimada
- Journal
- Nature Scientific Reports
- Year
- 2024
- DOI
- 10.1038/s41598-024-54542-7
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Ischemia-Reperfusion Injury
- Body System
- Digestive
TL;DR
A silicon-based antioxidant treatment reduces damage and cell death in the intestines caused by blood flow issues in mice.
Key Finding
A silicon-based agent that generates hydrogen in the intestinal tract reduced oxidative stress and cell death in a mouse model of small bowel ischemia-reperfusion injury while preserving the intestinal mucosal layer.
Summary
Researchers tested a silicon-based compound that produces hydrogen gas in the intestines to see if it could protect against ischemia-reperfusion injury—damage that occurs when blood flow to the small intestine is cut off and then restored. In mice, the treatment reduced cell damage by lowering oxidative stress (harmful chemical reactions) and preserved the protective lining of the intestine better than no treatment.
Practical Takeaway
This is early-stage research in mice only, so findings cannot yet be applied to humans. The study suggests hydrogen-generating compounds may eventually help prevent intestinal damage during transplantation, but much more research—including human trials—would be needed before any clinical use.
Abstract
The progression of small bowel ischemia-reperfusion (IR) injury causes cells in the intestinal tract to undergo necrosis, necessitating surgical resection, which may result in loss of intestinal function. Therefore, developing therapeutic agents that can prevent IR injury at early stages and suppress its progression is imperative. As IR injury may be closely related to oxidative stress, antioxidants can be effective therapeutic agents. Our silicon (Si)-based agent, an antioxidant, generated a large amount of hydrogen in the intestinal tract for a prolonged period after oral administration. As it has been effective for ulcerative colitis, renal failure, and IR injury during skin flap transplantation, it could be effective for small intestinal IR injury. Herein, we investigated the efficacy of an Si-based agent in a mouse model of small intestinal IR injury. The Si-based agent suppressed the apoptosis of small intestinal epithelial cells by reducing the oxidative stress induced by IR injury. In addition, the thickness of the mucosal layer in the small intestine of the Si-based agent-administered group was significantly higher than that in the untreated group, revealing that Si-based agent is effective against small intestinal IR injuries. In the future, Si-based agents may improve the success rate of small intestine transplantation.